Cargando…
βT87Q-Globin Gene Therapy Reduces Sickle Hemoglobin Production, Allowing for Ex Vivo Anti-sickling Activity in Human Erythroid Cells
Lentiviral addition of βT87Q-globin, a modified β-globin with an anti-sickling mutation, is currently being used in gene therapy trials for sickle cell disease (SCD) and β-thalassemia patients. βT87Q-globin interferes with sickle hemoglobin (HbS) polymerization. Here, we generated the SCD mutation i...
Autores principales: | Demirci, Selami, Gudmundsdottir, Bjorg, Li, Quan, Haro-Mora, Juan J., Nassehi, Tina, Drysdale, Claire, Yapundich, Morgan, Gamer, Jackson, Seifuddin, Fayaz, Tisdale, John F., Uchida, Naoya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210457/ https://www.ncbi.nlm.nih.gov/pubmed/32405513 http://dx.doi.org/10.1016/j.omtm.2020.04.013 |
Ejemplares similares
-
Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease
por: Uchida, Naoya, et al.
Publicado: (2021) -
High-Efficiency Lentiviral Transduction of Human CD34(+) Cells in High-Density Culture with Poloxamer and Prostaglandin E2
por: Uchida, Naoya, et al.
Publicado: (2019) -
Low-Dose Busulfan Reduces Human CD34(+) Cell Doses Required for Engraftment in c-kit Mutant Immunodeficient Mice
por: Leonard, Alexis, et al.
Publicado: (2019) -
Preclinical evaluation for engraftment of CD34(+) cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models
por: Uchida, Naoya, et al.
Publicado: (2021) -
CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease
por: Demirci, Selami, et al.
Publicado: (2021)